STOCK TITAN

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Verrica Pharmaceuticals Inc. announced that its President and CEO will present at upcoming investor conferences hosted by RBC Capital Markets and HCW BioConnect. The webcasts can be accessed on the company's website for 90 days after the events.

Positive
  • None.
Negative
  • None.

WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences:

RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 15, 2024
Time: 3:05 p.m. ET
Location: New York, NY

HCW BioConnect Conference
Date: Monday, May 20, 2024
Time: 10:00 a.m. ET
Location: New York, NY

The webcasts can be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, YCANTH® (cantharidin), became the first treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler 
Chief Financial Officer 
tkohler@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

Chris Calabrese 
LifeSci Advisors 
ccalabrese@lifesciadvisors.com


FAQ

When will Ted White present at the RBC Capital Markets Global Healthcare Conference?

Ted White will present on Wednesday, May 15, 2024, at 3:05 p.m. ET.

Where can the webcasts be accessed?

The webcasts can be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com.

How long will the webcasts be available?

The webcasts will be available for 90 days following the events.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals' stock symbol is VRCA.

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

VRCA Rankings

VRCA Latest News

VRCA Stock Data

56.32M
42.67M
34.54%
43.79%
8.69%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WEST CHESTER